Journal of Neurochemistry, 48(3), 760764
Summary comparison table Quick read: semaglutide remains the validated pillar with cardiovascular backing, tirzepatide dominates weight efficacy on solid data, and retatrutide pushes the frontier further at the cost of a dossier still consolidating
The FDA resolved the semaglutide and tirzepatide shortages in 2025, ending the broad shortage-based pathway that powered large-scale compounding, and in April 2026 proposed excluding these drugs from the 503B bulks list, with a comment period through June 29, 2026
The FDA also warns not to take Trulicity if you have a personal or family history of multiple endocrine neoplasia syndrome Type 2, medullary thyroid cancer, or insulin-dependent diabetes
If a Lipo C formula contains unusual additives, providers should verify ingredients with the supplying pharmacy